TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3239463

Group type: EXPERIMENTAL
Intervention: Nicotine gum with a self-help manual
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Self-help manual without gum
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control condition (no further treatment)
Number of subjects: 197
Study: 28743174

Group type: EXPERIMENTAL
Intervention: Group intervention to facilitate posttraumatic growth (PTG)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group (n=147)
Number of subjects: 205
Study: 26777321

Group type: EXPERIMENTAL
Intervention: Immediate intervention (<2 h after randomization)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Delayed intervention (2 to 72 h after randomization)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Immediate intervention
Number of subjects: 323

Group type: COMPARATOR
Intervention: Delayed intervention
Number of subjects: 323
Study: 25575728

Group type: EXPERIMENTAL
Intervention: Montelukast (4mg daily for 5 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 50
Study: 24085051

Group type: EXPERIMENTAL
Intervention: Topical regimen (2% hydroquinone, 1% hydrocortisone and 0.05% tretinoin) with serial glycolic acid peeling
Number of subjects: 40

Group type: COMPARATOR
Intervention: Topical regimen (2% hydroquinone, 1% hydrocortisone, 0.05% tretinoin)
Number of subjects: 40
Study: 20945011

Group type: EXPERIMENTAL
Intervention: Adolescents
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Adults
Number of subjects: 72

Group type: COMPARATOR
Intervention: Comparison between adolescents and adults
Number of subjects: 72
Study: 18439174

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus additional tilt training sessions
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 82
Study: 16714461

Group type: EXPERIMENTAL
Intervention: Theophylline (200 mg 30 minutes before contrast medium administration)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Acetylcysteine (600 mg twice daily on the day of and the day before the examination)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both agents combined (theophylline and acetylcysteine)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Acetylcysteine
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 91
Study: 15534843

Group type: EXPERIMENTAL
Intervention: Lipid lowering drug
Number of subjects: 6595

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6595
Study: 11282901

Group type: EXPERIMENTAL
Intervention: Low-dose metoprolol CR/XL (25 mg once daily)
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg once daily)
Number of subjects: 793

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 793
Study: 9001771

Group type: EXPERIMENTAL
Intervention: CSI soft toric contact lens
Number of subjects: 21

Group type: COMPARATOR
Intervention: Optima soft toric contact lens
Number of subjects: 21
Study: 7684157

Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 3324497

Group type: EXPERIMENTAL
Intervention: 20 mg nicergoline h.s.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10 mg nicergoline b.i.d.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (during the 2-week placebo period)
Number of subjects: 24
Study: 30958423

Group type: EXPERIMENTAL
Intervention: In-person group (n = 37)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Online group (n = 37)
Number of subjects: 74
Study: 29467200

Group type: EXPERIMENTAL
Intervention: Salford Lung Study (SLS)
Number of subjects: 0
Study: 26503414

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg once daily plus ribavirin 1000-1200 mg divided twice daily for 12 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg once daily plus ribavirin 1000-1200 mg divided twice daily for 16 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg once daily plus ribavirin 1000-1200 mg divided twice daily for 24 weeks
Number of subjects: 31
Study: 25237196

Group type: EXPERIMENTAL
Intervention: 3 doses of 50 μg varicella-zoster virus glycoprotein E (gE) adjuvanted with AS01B
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 3 doses of gE adjuvanted with AS01E
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 1 dose of saline followed by 2 doses of gE/AS01B
Number of subjects: 121

Group type: COMPARATOR
Intervention: 3 doses of saline
Number of subjects: 121
Study: 22503429

Group type: EXPERIMENTAL
Intervention: Therapeutic exercise regimen for 4 weeks
Number of subjects: 30
Study: 20736679

Group type: EXPERIMENTAL
Intervention: Web-based educational intervention (CME activities)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 133
Study: 18809614

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with paclitaxel 200 mg/m² and carboplatin AUC 6 mg/mL/min every 3 weeks for four cycles
Number of subjects: 344

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 344
Study: 16278616

Group type: EXPERIMENTAL
Intervention: 1 mg micronized 17beta‐estradiol daily
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 11914254

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter‐defibrillator (ICD) therapy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study: 9860147

Group type: EXPERIMENTAL
Intervention: Enalapril (0.5 mg) at pH 5
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Lisinopril (0.5 mg) at pH 6
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Enalapril (0.06 mmol x l(‐1)) with cephradine (0.05 mmol x l(‐1))
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Lisinopril (0.057 mmol x l(‐1)) with cephradine (0.05 mmol x l(‐1))
Number of subjects: 6
Study: 7884114

Group type: EXPERIMENTAL
Intervention: Psyllium fiber (Metamucil) 3.4 g
Number of subjects: 15

Group type: COMPARATOR
Intervention: Neutral cellulose
Number of subjects: 15

Group type: COMPARATOR
Intervention: No added fiber
Number of subjects: 15
Study: 2404487

Group type: EXPERIMENTAL
Intervention: 0.008% timolol ophthalmic solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.25% timolol ophthalmic solution
Number of subjects: 0
Study: 57570

Group type: EXPERIMENTAL
Intervention: Disopyramide phosphate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31040122

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg once daily
Number of subjects: 817

Group type: COMPARATOR
Intervention: Adalimumab 40 mg biweekly
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Baricitinib (rescued patients)
Number of subjects: 817

Group type: COMPARATOR
Intervention: Adalimumab (rescued patients)
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Baricitinib (switched from adalimumab)
Number of subjects: 817

Group type: COMPARATOR
Intervention: Baricitinib and Adalimumab (continuing treatment)
Number of subjects: 817
Study: 28542164

Group type: EXPERIMENTAL
Intervention: Providing information to late payers
Number of subjects: 4298
Study: 25322473

Group type: EXPERIMENTAL
Intervention: Patient decision aid (N=63)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Treatment as usual (control group, N=65)
Number of subjects: 132
Study: 23556434

Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles Programme (HeLP)
Number of subjects: 1300
Study: 21576561

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 21
Study: 19891014

Group type: EXPERIMENTAL
Intervention: Magnetization transfer imaging (MTI)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 19
Study: 17383283

Group type: EXPERIMENTAL
Intervention: Early invasive treatment strategy
Number of subjects: 1141

Group type: COMPARATOR
Intervention: Selective invasive strategy
Number of subjects: 1141

Group type: EXPERIMENTAL
Intervention: NT-proBNP (highest quartile > or = 1170 ng/L for men, > or = 2150 ng/L for women)
Number of subjects: 1141

Group type: COMPARATOR
Intervention: NT-proBNP (lower 3 quartiles)
Number of subjects: 1141

Group type: EXPERIMENTAL
Intervention: NT-proBNP levels
Number of subjects: 1141
Study: 15576015

Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg administered orally under fasting conditions
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg administered orally under fed conditions
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg administered orally with food
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 6
Study: 11236774

Group type: EXPERIMENTAL
Intervention: Transplantation of human embryonic dopamine neurons
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Transplantation of human embryonic dopamine neurons (younger patients)
Number of subjects: 40
Study: 9604553

Group type: EXPERIMENTAL
Intervention: Nicotine patch treatment
Number of subjects: 0
Study: 8085581

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins and trace minerals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observational studies
Number of subjects: 0
Study: 3242578

Group type: EXPERIMENTAL
Intervention: Apomorphine (0.009 mg kg‐1 subcutaneous route)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Yohimbine (0.30 mg kg‐1 i.v. route)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 17894079

Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30851091

Group type: EXPERIMENTAL
Intervention: Pallidal deep brain stimulation
Number of subjects: 105
Study: 28052841

Group type: EXPERIMENTAL
Intervention: Web-based guided self-help intervention (cognitive-behavioral therapy and problem-solving therapy) in addition to usual care
Number of subjects: 406

Group type: COMPARATOR
Intervention: Usual care supplemented with Web-based psycho-education (enhanced usual care)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Web-based guided self-help intervention
Number of subjects: 406
Study: 25848812

Group type: EXPERIMENTAL
Intervention: Acceptance‐ and commitment‐based group (ACT + FB)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Feedback group (FB)
Number of subjects: 138
Study: 23578686

Group type: EXPERIMENTAL
Intervention: Mitii training (20 weeks, 30 min daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control (20 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mitii training
Number of subjects: 0
Study: 22134973

Group type: EXPERIMENTAL
Intervention: Aripiprazole + Divalproex
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo + Divalproex
Number of subjects: 83
Study: 20134038

Group type: EXPERIMENTAL
Intervention: Epworth Sleepiness Scale (ESS)
Number of subjects: 458
Study: 16769956

Group type: EXPERIMENTAL
Intervention: Dopamine agonists
Number of subjects: 297

Group type: COMPARATOR
Intervention: No dopamine agonists
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Potent D3 receptor agonist
Number of subjects: 297
Study: 15315398

Group type: EXPERIMENTAL
Intervention: Grape seed extract (1000 mg/day total polyphenols)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 11503008

Group type: EXPERIMENTAL
Intervention: Erythromycin (500 mg, 3 times daily for 4 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: DHEC (10 mg, administered alone)
Number of subjects: 9
Study: 9250182

Group type: EXPERIMENTAL
Intervention: Continuous hyperfractionated accelerated radiotherapy (CHART) - 36 fractions of 1.5 Gy given three times per day for a total of 54 Gy in 12 days
Number of subjects: 563

Group type: COMPARATOR
Intervention: Conventional radiotherapy - 30 fractions of 2 Gy for a total dose of 60 Gy in 6 weeks
Number of subjects: 563
Study: 8487006

Group type: EXPERIMENTAL
Intervention: Low-salt intake (2.8 +/- 1.0 g day-1 of NaCl)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Salt supplements (11.7 +/- 2.5 g day-1 of NaCl)
Number of subjects: 30
Study: 3661951

Group type: EXPERIMENTAL
Intervention: Injection of an opioid prior to methohexital and addition of lidocaine to the methohexital solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 0
Study: 29895330

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (5-10 mg/day)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Sitagliptin (50-100 mg/day)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 340

Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 340
Study: 26710224

Group type: EXPERIMENTAL
Intervention: Topical lidocaine 2% gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 60
Study: 25198032

Group type: EXPERIMENTAL
Intervention: Standard endoscopic monitor with AR navigation displayed on a submonitor (SM)
Number of subjects: 50

Group type: COMPARATOR
Intervention: AR as a single display
Number of subjects: 50
Study: 22641307

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 72
Study: 20717951

Group type: EXPERIMENTAL
Intervention: Fexofenadine with montelukast
Number of subjects: 275

Group type: COMPARATOR
Intervention: Fexofenadine alone
Number of subjects: 275

Group type: COMPARATOR
Intervention: Fexofenadine with placebo
Number of subjects: 275
Study: 19025037

Group type: EXPERIMENTAL
Intervention: Thermal pain stimulation (46 degrees C for 6 min)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No pain stimulation
Number of subjects: 60
Study: 16354850

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA-rich supplement (400 kilocalories per day)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA-rich supplement
Number of subjects: 64

Group type: COMPARATOR
Intervention: Omega-3 PUFA-nonrich supplement
Number of subjects: 64
Study: 12552051

Group type: EXPERIMENTAL
Intervention: Droperidol 2.75 mg
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Droperidol 5.5 mg
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Droperidol 8.25 mg
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study: 14578939

Group type: EXPERIMENTAL
Intervention: In-situ radiofrequency ablation (RA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Milligan-Morgan hemorrhoidectomy (MM)
Number of subjects: 40
Study: 9448552

Group type: EXPERIMENTAL
Intervention: Zileuton 400 mg 4 times daily
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Zileuton 600 mg 4 times daily
Number of subjects: 313

Group type: COMPARATOR
Intervention: Theophylline (dosage titrated to achieve trough concentrations of 8 to 15 micrograms/mL)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: All groups (including both zileuton dosages and theophylline)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 313
Study: 8537988

Group type: EXPERIMENTAL
Intervention: Incentive spirometry
Number of subjects: 0
Study: 2615523

Group type: EXPERIMENTAL
Intervention: Morning intravenous administration of 4' epi-adriamycin (45 mg m-2)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Afternoon intravenous administration of 4' epi-adriamycin (45 mg m-2)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Morning and afternoon dosing of 4' epi-adriamycin
Number of subjects: 10
Study: 342181

Group type: EXPERIMENTAL
Intervention: Stannous fluoride mouthrinse (100 parts/10(6)F‐)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Stannous fluoride mouthrinse (200 parts/10(6)F‐)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study: 30198084

Group type: EXPERIMENTAL
Intervention: Eye screening (50%)
Number of subjects: 3039

Group type: COMPARATOR
Intervention: Control (50%)
Number of subjects: 3039
Study: 28672291

Group type: EXPERIMENTAL
Intervention: INTERACT training and support
Number of subjects: 36717

Group type: COMPARATOR
Intervention: Control group (no INTERACT training)
Number of subjects: 36717
Study: 25366811

Group type: EXPERIMENTAL
Intervention: Accelerated programme (AP)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard programme (SP)
Number of subjects: 51
Study: 23644953

Group type: EXPERIMENTAL
Intervention: 10 min film based on intergroup contact theory
Number of subjects: 925

Group type: EXPERIMENTAL
Intervention: Film based on a protest message
Number of subjects: 925

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 925
Study: 21983248

Group type: EXPERIMENTAL
Intervention: TPA (25 μg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: F/U (follow-up)
Number of subjects: 27

Group type: COMPARATOR
Intervention: IVB (1.25 mg of bevacizumab)
Number of subjects: 27
Study: 19366494

Group type: EXPERIMENTAL
Intervention: New Clinical Pathway (NCP)
Number of subjects: 3434

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 3434
Study: 16448621

Group type: EXPERIMENTAL
Intervention: HPLC-tandem mass spectrometry (HPLC-MS-MS) for quantitation of plasma total 15-series PGF isomers and AA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPLC-MS-MS
Number of subjects: 0
Study: 15265286

Group type: EXPERIMENTAL
Intervention: Cultured artificial bone grafted into the abdominal cavity of nude mice
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Porous ceramics impregnated with marrow cells subcultured in osteogenic culture medium
Number of subjects: 27
Study: 10678339

Group type: EXPERIMENTAL
Intervention: Regular vaginal pH testing
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Vaginal symptoms or pH level >4.5
Number of subjects: 121
Study: 9279201

Group type: EXPERIMENTAL
Intervention: Intermediate NaCl diet (120 mmol)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low NaCl diet (20 mmol)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High NaCl diet (240 mmol)
Number of subjects: 30
Study: 8285365

Group type: EXPERIMENTAL
Intervention: Ozone therapy (endovenous)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ozone therapy (intramuscular)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ozone therapy (rectal)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional medical treatment (control group)
Number of subjects: 72
Study: 30359300

Group type: EXPERIMENTAL
Intervention: Probiotic lactobacilli (Lactobacillus reuteri)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 27121699

Group type: EXPERIMENTAL
Intervention: Continuous moderate intensity aerobic exercise (CAE) for 30 minutes at 50% of maximum aerobic work
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High intensity interval aerobic exercise (hIAE) for 30 minutes at maximum aerobic work
Number of subjects: 20
Study: 24480902

Group type: EXPERIMENTAL
Intervention: Participation in the randomized double-blind placebo-controlled trial (Sugar Babies Study)
Number of subjects: 481

Group type: COMPARATOR
Intervention: Routine clinical care (heel lance blood tests)
Number of subjects: 481
Study: 22921698

Group type: EXPERIMENTAL
Intervention: Daily vardenafil 10 mg
Number of subjects: 74
Study: 20351239

Group type: EXPERIMENTAL
Intervention: Study protocol (Guidelines 2005)
Number of subjects: 845

Group type: COMPARATOR
Intervention: Control protocol (Guidelines 2000)
Number of subjects: 845
Study: 18514907

Group type: EXPERIMENTAL
Intervention: Urtica dioica (nettle sting) daily for 1 week
Number of subjects: 42

Group type: COMPARATOR
Intervention: Urtica galeopsifolia (placebo) daily for 1 week
Number of subjects: 42
Study: 15452188

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (40,000 U once weekly)
Number of subjects: 354
Study: 12616254

Group type: EXPERIMENTAL
Intervention: New MOW program (3 meals and 2 snacks per day, 7 days a week, meeting 100% of the Daily Reference Intake)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Traditional MOW program (5 hot meals per week, meeting 33% of the Daily Reference Intake)
Number of subjects: 203
Study: 10806125

Group type: EXPERIMENTAL
Intervention: OPCAB procedure using a suction device and regular sternotomy
Number of subjects: 26

Group type: COMPARATOR
Intervention: CABG using extracorporeal circulation, blood cardioplegia and hypothermic arrest
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: OPCAB procedure
Number of subjects: 26

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: OPCAB
Number of subjects: 26
Study: 8915025

Group type: EXPERIMENTAL
Intervention: 0.03% chlorhexidine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 1% co-polymer and 0.03% chlorhexidine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 1% co-polymer
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study: 1802131

Group type: EXPERIMENTAL
Intervention: Gadodiamide injection
Number of subjects: 30
Study: 6412266

Group type: EXPERIMENTAL
Intervention: Alcohol administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no alcohol)
Number of subjects: 0
Study: 31653265

Group type: EXPERIMENTAL
Intervention: Anodal tsDCS
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cathodal tsDCS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham tsDCS
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: C3-T3 montage
Number of subjects: 10
Study: 29384020

Group type: EXPERIMENTAL
Intervention: Wup34min (warm-up protocol of 34 min)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Wup17min (warm-up protocol of 17 min)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both warm-up protocols (Wup34min and Wup17min)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Greater perceived muscular load (RPEMUSC)
Number of subjects: 18
Study: 26554025

Group type: EXPERIMENTAL
Intervention: Prasugrel (potent irreversible P2Y12 inhibitor)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 20
Study: 24980739

Group type: EXPERIMENTAL
Intervention: Zirconia restorations
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Lithium disilicate crowns
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Metal ceramic crowns
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (unprepared or minimally restored tooth)
Number of subjects: 22